By Fineline Cube 
China-based Peijia Medical Ltd (HKG: 9996) announced the successful completion of the first patient implantation in the global clinical study for its innovative MonarQ TTVR system. This milestone marks a significant advancement in the treatment of tricuspid regurgitation (TR).
MonarQ TTVR System Innovation
The MonarQ TTVR system is specifically designed to address tricuspid regurgitation with a unique biodynamic attachment system. This innovative design securely anchors to the native valve leaflets while preserving the heart’s natural motion. By sharing the systolic load and accommodating a wide range of native annulus sizes, the device minimizes paravalvular leakage (PVL).
Clinical Significance
The successful implantation demonstrates the feasibility and potential effectiveness of the MonarQ TTVR system in clinical practice. This achievement paves the way for further evaluation of the device in treating patients with TR, offering a promising new option for this challenging condition.-Fineline Info & Tech